Distribution of Streptococcus pneumoniae serotypes responsible for penicillin resistance and the potential role of new conjugate vaccines in New Caledonia

Journal of Clinical Microbiology

Volumn 43, Issue 12, 2005, Pages 6060-6063

  Michel, N ^a,c   Watson, M ^b,d   Baumann, F ^a   Perolat, P ^a   Garin, B ^a  

^a INSTITUT PASTEUR DE DAKAR   (Senegal)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c Institut Pasteur ^*  (France)

^d HOLLYWOOD PRIVATE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; PNEUMOCOCCUS VACCINE;

ADULT; AGE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DEMOGRAPHY; EUROPE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEW CALEDONIA; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ADULT; AGED; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; NEW CALEDONIA; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEASONS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 30744470157     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.12.6060-6063.2005     Document Type: Article

References (17)

1. Black, S. B., H. R. Shinefield, J. Hansen, L. Elvin, D. Laufer, and F. Malinoski. 2001. Post licensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 20:1105-1107.
2. Black, S., and H. Shinefield. 2002. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. Eur. J. Pediatr. 161:127-131.
3. Brueggemann, A. B., and B. G. Spratt. 2003. Geographic distribution and clonal diversity of Streptococcus pneumoniae scrotype 1 isolates. J. Clin. Microbiol. 41:4966-4970.
4. Dagan, R., N. Givon-Lavi, L. Shkolnik, P. Yagupsky, and D. Fraser. 2000. Acute otitis media caused by antibiotic-resistant Streptococcus pneumoniae in southern Israel: implication for immunizing with conjugate vaccines. J. Infect. Dis. 81:1322-1329.
5. Hausdorff, W. P., G. Yothers, R. Dagan, T. Kilpi, S. I. Pelton, R. Cohen, M. R. Jacobs, S. L. Kaplan, C. Levy, E. L. Lopez, E. O. Mason, Jr., V. Syriopoulou, B. Wynne, and J. Bryant. 2002. Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr. Infect. Dis. J. 21:1008-1016.
6. Hogg, G., and J. Stachan. 1999. Pneumococcal infections in Victoria, Australia. Vaccine 17:119-121.
7. Jette, L. P., and F. Lamothe. 1989. Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility, and clinical characteristics. J. Clin. Microbiol. 27:1-5.
8. Kertesz, D. A., J. L. Di Fabio, M. C. de Cunto Brandileone, E. Castaneda, G. Echaniz-Aviles, I. Heitmann, A. Homma, M. Hortal, M. Lovgren, R. O. Ruvinsky, J. A. Talbot, J. Weekes, and J. S. Spika. 1998. Invasive Streptococcus pneumoniae infection in Latin American children: results of the Pan American Health Organization Surveillance Study. Clin. Infect. Dis. 26: 1355-1361.
9. Kim, P. E., D. M. Musher, W. P. Glezen, M. C. Rodriguez-Barradas, W. K. Nahm, and C. E. Wright. 1996. Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. Clin. Infect. Dis. 22:100-106.
10. Krause, V. L., S. J. Reid, and A. Merianos. 2000. Invasive pneumococcal disease in the Northern Territory of Australia, 1994-1998. Med. J. Aust. 173(Suppl.):S27-S31.
11. Nielsen, S. V., K. Poulsen, L. M. Jorgensen, E. Rasmussen, S. Sanders, and J. Henrichsen. 1992. Incidence and diagnosis of pneumococcal pneumonias requiring admission to hospital. Ugeskr. Laeger. 154:412-415.
12. Riley, I. D., D. Lehmann, and M. P. Alpers. 1991. Pneumococcal vaccine trials in Papua New Guinea: relationships between epidemiology of pneumococcal infection and efficacy of vaccine. Rev. Infect. Dis. 13:535-541.
13. Vaccine Impact Surveillance Network-Invasive Pneumococcal Study Group. 2000. Are current recommendations for pneumococcal vaccination appropriate for Western Australia? Med. J. Aust. 173(Suppl.):S36-S40.
14. Vergnaud, M., S. Bourdon, M. Brun, B. Cattier, C. Chanal, H. Chardon et al. 2003. Observatoires régionaux du pneumocoque: analyse de la résistance aux antibiotiques et des sérotypes de Streptococcus pneumoniae en 2001. BEH 37:173-176.
15. Whitney, C. G., M. M. Parley, J. Hadler, L. H. Harrison, N. M. Bennett, R. Lynfield, A. Reingold, P. R. Cieslak, T. Pilishvili, D. Jackson, R. R. Facklam, J. H. Jorgensen, and A. Schuchat. 2003. Active Bacterial Core Surveillance of the Emerging Infections Program Network: decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-1746.
16. Yagupsky, P., N. Porat, D. Fraser, F. Prajgrod, M. Merires, L. McGee, K. P. Klugman, and R. Dagan. 1998. Acquisition, carriage, and transmission of pneumococci with decreased antibiotic susceptibility in young children attending a day care facility in southern Israel. J. Infect. Dis. 177:1003-1012.
17. Zangwill, K. M., C. M. Vadheim, A. M. Vannier, L. S. Hemenway, D. P. Greenberg, and J. I. Ward. 1996. Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J. Infect. Dis. 174:752-759.